{"id":13531,"date":"2011-01-11T06:30:00","date_gmt":"2011-01-11T05:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/il-botox-di-allergan-tiene-in-piedi-lirlanda\/"},"modified":"2011-01-11T06:30:00","modified_gmt":"2011-01-11T05:30:00","slug":"il-botox-di-allergan-tiene-in-piedi-lirlanda","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/il-botox-di-allergan-tiene-in-piedi-lirlanda\/","title":{"rendered":"Allergan&#039;s Botox keeps Ireland on its feet"},"content":{"rendered":"<p><font size=\"3\"><\/font><\/p>\n<p><font size=\"3\"><\/font><\/p>\n<p><font size=\"3\">Despite the crisis in Europe, in Ireland in Westport, the plant that produces Allergan&#039;s anti-wrinkle Botox (botulinum toxin) worldwide reports +10% of annual profits. Currently Botox revenue is split 50% between cosmetic and therapeutic uses, by 2016 70% of revenue will come from therapeutic use, for chronic migraine. In about 20 years, the plant has produced more than 26 million vials, generating 370 million euros in annual turnover.<\/font><\/p>\n<p><em>( la Repubblica Pag.29 \u2013 10\/01\/2011 ) <img loading=\"lazy\" decoding=\"async\" class=\"rg_hi\" id=\"rg_hi\" style=\"width: 96px; height: 22px\" height=\"22\" alt=\"\" width=\"96\" data-width=\"96\" data-height=\"22\" src=\"http:\/\/t0.gstatic.com\/images?q=tbn:ANd9GcTJaC-gsJDFZ-vsu4cUPK6qBiBGPpi10TXMjpkZKAeQNqkPrdVb\" \/><\/em><\/p>\n<p align=\"center\"><img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" style=\"padding-right: 8px; padding-bottom: 8px; padding-top: 8px\" height=\"157\" alt=\"\" width=\"280\" src=\"http:\/\/www.pharmaceutical-industry.info\/modules\/pharmaceutical_suppliers\/allergan\/images\/allergan-factory.jpg\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Nonostante la crisi d&#8217;Europa, in Irlanda a Westport, lo stabilimento che produce a livello mondiale l&#8217;antirughe Botox (tossina botulinica) di Allergan segna un +10% di profitti annuo. Attualmente le entrate di Botox sono divise al 50% tra usi cosmetici e terapeutici, entro il 2016 il 70% del fatturato verr&agrave; dall&#8217;uso terapeutico, per l&#8217;emicrania cronica. In &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13531"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13531\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}